|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Glycyrrhizin attenuates HMGB1-induced hepatocyte apoptosis by inhibiting the p38-dependent mitochondrial pathway显示文摘AIM:To examine how high-mobility group box 1 (HMGB1) regulates hepatocyte apoptosis and,furthermore,to determine whether glycyrrhizin (GL),a known HMGB1 inhibitor,prevents HMGB1-induced hepatocyte apoptosis.METHODS:A human hepatocellular carcinoma cell line stably transfected with a bile acid transporter (HuhBAT cells),were used in this study.Apoptosis was quantified using 4',6-diamidino-2-phenylindole dihydrochloride staining and the APO Percentage apoptosis assay,and its signaling cascades were explored by immunoblot analysis.Kinase signaling was evaluated by immunoblotting and by using selective inhibitors.It is also tried to identify hepatocyte apoptosis affected by the HMGB1 inhibitor,GL.RESULTS:HMGB1 increased cellular apoptosis in HuhBAT cells.HMGB1 led to increased cytochrome c release from mitochondria into the cytosol,and induced the cleavage of procaspase 3.However,it did not affect the activation of caspase 8.HMGB1-induced caspase 3 activation was significantly attenuated by the p38 inhibitor SB203580.GL significantly attenuated HMGB1-induced hepatocyte apoptosis.GL also prevented HMGB1-induced cytochrome c release and p38 activation in Huh-BAT cells.CONCLUSION:The present study demonstrated that HMGB1 promoted hepatocyte apoptosis through a p38dependent mitochondrial pathway.In addition,GL had an anti-apoptotic effect on HMGB1-treated hepatocytes. | Geum-Youn Gwak Tae Gun Moon Dong Ho Lee Byung Chul Yoo | 2012 | World Journal of Gastroenterology2012，18，7： | 26 |
| 2 | Tenofovir rescue therapy for chronic hepatitis B patients after multiple treatment failures显示文摘AIM:To evaluate the efficacy and safety of tenofovir disoproxil fumarate(TDF) for chronic hepatitis B(CHB) patients after multiple failures.METHODS:A total of 29 CHB patients who had a suboptimal response or developed resistance to two or more previous nucleoside/nucleotide analogue(NA) treatments were included.Study subjects were treated with TDF alone(n = 13) or in combination with lamivudine(LAM,n = 12) or entecavir(ETV,n = 4) for ≥ 6 mo.Complete virologic response(CVR) was defined as an achievement of serum hepatitis B virus(HBV) DNA level ≤ 60 IU/mL by real-time polymerase chain reaction method during treatment.Safety assessment was based on serum creatinine and phosphorus level.Eleven patients had histories of LAM and adefovir dipivoxil(ADV) treatment and 18 patients were exposed to LAM,ADV,and ETV.Twenty-seven patients(93.1%) were hepatitis B e antigen(HBeAg) positive and the mean value of the baseline serum HBV DNA level was 5.5 log IU/mL ± 1.7 log IU/mL.The median treatment duration was 16 mo(range 7 to 29 mo).RESULTS:All the patients had been treated with LAM and developed genotypic and phenotypic resistance to it.Resistance to ADV was present in 7 patients and 10 subjects had a resistance to ETV.One patient had a resistance to both ADV and ETV.The cumulative probabilities of CVR at 12 and 24 mo of TDF containing treatment regimen calculated by the Kaplan Meier method were 86.2% and 96.6%,respectively.Although one patient failed to achieve CVR,serum HBV DNA level decreased by 3.9 log IU/mL from the baseline and the last serum HBV DNA level during treatment was 85 IU/mL,achieving near CVR.No patients in this study showed viral breakthrough or primary non-response during the follow-up period.The cumulative probability of HBeAg clearance in the 27 HBeAg positive patients was 7.4%,12%,and 27% at 6,12,and 18 mo of treatment,respectively.Treatment efficacy of TDF containing regimen was not statistically different according to the presence of specific HBV mutations.History of prior exposure to specific antiviral agents did not make a difference to treatment outcome.Treatment efficacy of TDF was not affected by combination therapy with LAM or ETV.No patient developed renal toxicity and no cases of hypophosphatemia associated with TDF therapy were observed.There were no other adverse events related to TDF therapy observed in the study subjects.CONCLUSION:TDF can be an effective and safe rescue therapy in CHB patients after multiple NA therapy failures. | Yu Jin Kim Dong Hyun Sinn Geum-Youn Gwak Moon Seok Choi Kwang Cheol Koh Seung Woon Paik Byung Chul Yoo Joon Hyeok Lee | 2012 | World Journal of Gastroenterology2012，18，47： | 16 |
| 3 | Small molecule-based disruption of the Axin/β-catenin protein complex regulates mesenchymal stem cell differentiation显示文摘 | Jungsug Gwak Sun Gwan Hwang Hyung-Soon Park Sang Rak Choi Sun-Hee Park Hyunjoon Kim Nam-Chul Ha Sung Jin Bae Jin-Kwan Han Dong-Eun Kim Jeong Woo Cho Sangtaek Oh | 2012 | Cell Research2012，22，1： | 11 |
| 4 | Virological response to adefovir monotherapy and the risk of adefovir resistance显示文摘AIM:To evaluate virological response to adefovir(ADV) monotherapy and emergence of ADV-resistant mutations in lamivudine(LAM)-resistant chronic hepatitis B patients.METHODS:Seventy-seven patients with documented LAM resistance who were treated with 10 mg/d ADV for>96 wk were analyzed for ADV resistance.RESULTS:At week 48 and 96,eight(10%)and 14(18%)of 77 LAM-resistant patients developed the ADV-resistant strain(rtA181V/T and/or rtN236T mutations),respectively.Hepatitis B virus(HBV)DNA levels during therapy were significantly higher in patients who developed ADV resistance than in those who did not.Incidence of ADV resistance at week 96 was 11%,8%and 6%among patients with complete virological response(HBV DNA level<60 IU/mL);0%,5%and 19%among patients with partial virological response(HBV DNA level≥60 to 2000 IU/mL);and 32%,34% and 33%among patients with inadequate virological response(HBV DNA levels>2000 IU/mL)at week 12,week 24 and week 48,respectively.HBV DNA levels >2000 IU/mL at week 24 showed best performance characteristics in predicting ADV resistance.CONCLUSION:Development of ADV resistance mutations was associated with HBV DNA levels,which could identify patients with LAM resistance who are likely to respond to ADV monotherapy. | Dong Hyun Sinn Geum-Youn Gwak Moon Seok Choi Kwang Cheol Koh Seung Woon Paik Byung Chul Yoo Joon Hyeok Lee Hyang Ie Lee | 2011 | World Journal of Gastroenterology2011，17，30： | 5 |
| 5 | The feasibility of combined transcatheter arterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma显示文摘 | Ju‐Yeon Cho Yong‐Han Paik Hee Chul Park Jeong Il Yu Won Sohn Geum‐Youn Gwak Moon Seok Choi Joon Hyeok Lee Kwang Cheol Koh Seung Woon Paik Byung Chul Yoo | 2014 | Liver Int2014，，5： | 5 |
| 6 | 覆盆子对酒精戒断大鼠海马中去甲肾上腺素的作用显示文摘目的:研究覆盆子对酒精戒断焦虑症的治疗作用,并探讨起对脑内海马组织中去甲肾上腺素的机制。方法:选取健康SD大鼠36只,体重220~250 g,随机分为6组,空白组、模型组、高剂量药物组、中剂量药物组、低剂量药物组、阳性药物组。除空白组外,其余5组每天腹腔内注射20%(w/v)酒精1.5 ml/100 g,共28天,制备酒精成瘾模型,然后灌胃不同剂量药物,每天一次,共给3天,最后一次给药1 h后,用高架十字迷宫测其焦虑行为,断头取脑,分离海马,用HPLC测海马中去甲肾上腺素的含量。结果:在高架十字迷宫中,与空白对照组相比,酒精戒断大鼠在开放臂的逗留次数、时间明显减少(P<0.01);与模型组相比,高剂量覆盆子提取物显著地增加其次数、时间(P<0.05),而中、低剂量覆盆子提取物作用效果不明显(P>0.05);HPLC检测显示与空白组相比,酒精成瘾大鼠海马中去甲肾上腺素的含量显著升高(P<0.01),与模型组相比,高剂量覆盆子可降低海马中去甲肾上腺素含量(P<0.05),中、低剂量覆盆子降低去甲肾上腺素含量的趋势不明显(P>0.05)。结论:覆盆子提取物能减轻酒精戒断时大鼠所表现出的焦虑样行为,其抗焦虑症的作用机制可能与降低大鼠脑内海马组织中去甲肾上腺素含量有关。 | 邢宇双 吴宜艳 梁启超 杨志 赵容杰 Young Seob Gwak | 2018 | 中医药学报2018，46，1： | 5 |
| 7 | High-risk esophageal varices in patients treated with locoregional therapy for hepatocellular carcinoma:Assessment with liver computed tomography显示文摘AIM:To assess the diagnostic performance of followup liver computed tomography(CT) for the detection of high-risk esophageal varices in patients treated with locoregional therapy for hepatocellular carcinoma(HCC).METHODS:We prospectively enrolled 100 patients with cirrhosis who underwent transcatheter arterial chemoembolization,radiofrequency ablation or both procedures for HCCs.All patients underwent upper endoscopy and subsequently liver CT.Three radiologists independently evaluated the presence of high-risk esophageal varices with transverse images alone and with three orthogonal multiplanar reformation(MPR) images,respectively.With endoscopic grading as the reference standard,diagnostic performance was assessed by using receiver operating characteristic(ROC) curve analysis.RESULTS:The diagnostic performances(areas under the ROC curve) of three observers with transverse images alone were 0.947 ± 0.031,0.969 ± 0.024,and 0.916 ± 0.038,respectively.The mean sensitivity,specificity,positive predicative value(PPV),and negative predicative value(NPV) with transverse images alone were 90.1%,86.39%,70.9%,and 95.9%,respectively.The diagnostic performances,mean sensitivity,specificity,PPV,and NPV with three orthogonal MPR images(0.965 ± 0.025,0.959 ± 0.027,0.938 ± 0.033,91.4%,89.5%,76.3%,and 96.6%,respectively) were not superior to corresponding values with transverse images alone(P > 0.05),except for the mean specificity(P = 0.039).CONCLUSION:Our results showed excellent diagnostic performance,sensitivity and NPV to detect high-risk esophageal varices on follow-up liver CT after locoregional therapy for HCC. | Hyojin Kim Dongil Choi Joon Hyeok Lee Soon Jin Lee Hangi Jo Geum-Youn Gwak Kwang Cheol Koh Moon Seok Choi Seonwoo Kim | 2012 | World Journal of Gastroenterology2012，18，35： | 4 |
| 8 | The Relationship Between Inhalational Anesthetic Requirements and the Severity of Liver Disease in Liver Transplant Recipients According to Three Phases of Liver Transplantation显示文摘 | J.G. Kang J.S. Ko G.S. Kim M.S. Gwak Y.R. Kim S.-K. Lee | 2010 | Transplantation Proceedings2010，，3： | 2 |
| 9 | Does General Anesthesia With Inhalation Anesthetics Worsen Hypoxemia in Patients With End-Stage Liver Disease and an Intrapulmonary Shunt?显示文摘 | J.A. Kim J.J. Lee C.S. Kim I.S. Chung M.S. Gwak G.S. Kim | 2011 | Transplantation Proceedings2011，，5： | 2 |
| 10 | Pre-S Mutation Is a Significant Risk Factor for Hepatocellular Carcinoma Development: A Long-Term Retrospective Cohort Study显示文摘 | Dong Hyun Sinn Moon Seok Choi Geum-Youn Gwak Yong-Han Paik Joon Hyeok Lee Kwang Cheol Koh Seung Woon Paik Byung Chul Yoo | 2013 | Digestive Diseases and Sciences2013，，3： | 2 |
| 11 | Promotion of Hepatocellular Carcinoma by the Intestinal Microbiota and TLR4显示文摘 | Dianne H. Dapito Ali Mencin Geum-Youn Gwak Jean-Philippe Pradere Myoung-Kuk Jang Ingmar Mederacke Jorge M. Caviglia Hossein Khiabanian Adebowale Adeyemi Ramon Bataller Jay H. Lefkowitch Maureen Bower Richard Friedman R. Balfour Sartor Raul Rabadan Robert | 2012 | Cancer Cell2012，，4： | 2 |
| 12 | Modulation of Hepatic Fibrosis by c-Jun-N-Terminal Kinase Inhibition显示文摘 | Johannes Kluwe Jean–Philippe Pradere Geum–Youn Gwak Ali Mencin Samuele De Minicis Christoph H. ?sterreicher Jordi Colmenero Ramon Bataller Robert F. Schwabe | 2010 | Gastroenterology2010，，1： | 2 |
| 13 | HBV DNA and HBsAg Levels as Risk Predictors of Early and Late Recurrence after Curative Resection of HBV-related Hepatocellular Carcinoma显示文摘 | Won Sohn Yong-Han Paik Jong Man Kim Choon Hyuk Kwon Jae Won Joh Ju Yeon Cho Geum-Youn Gwak Moon Seok Choi Joon Hyeok Lee Kwang Cheol Koh Seung Woon Paik Byung Chul Yoo | 2014 | Annals of Surgical Oncology2014，，7： | 2 |
| 14 | Spatial and temporal activation of spinal glial ceils : role of gliopathy in central neuropathic pain fol- lowing spinal cord in rats 显示文摘 | Gwak YS Kang J Unabia GC | 2012 | Exp Neurol2012，234，： | 1 |
| 15 | Synthesis of indium tin oxide (ITO) and fluorine-doped tin oxide (FTO) nano-powder by sol-gel combustion hybrid method显示文摘 | Han C H Han S D Gwak J | | 0，，8： | 1 |
| 16 | Synthesis of indi- um tin oxide (ITO) and fluorine-doped tin oxide (FTO) nano- powder by sol-gel combustion hybrid method显示文摘 | Han Chihwan: Han Sangdo Jihye Gwak | 2007 | Materials Let- ters2007，61，89： | 1 |
| 17 | Clinicopathologic characteristics and long-term prognosis of scirrhous hepatocellular carcinoma显示文摘 | Lee JH Choi MS Gwak GY | 2012 | Dig Dis Sci2012，57，6： | 1 |
| 18 | The protective effect of is- chemic preconditioning against hepatic ischemic-repeffusion in- jury under isoflurane anesthesia in rats显示文摘 | KO JS GWAK MS KIM GS | 2013 | Transplantation Pro- ceedings2013，45，5： | 1 |
| 19 | Application of extremum seeking control to turbodynamic blood pumps显示文摘 | GWAK K W | 2007 | ASAIO Journal2007，53，4： | 1 |
| 20 | The incidence and clinical outcome of YMDD mutants in hepatitis B surface antigen-positive renal al- lograft recipients after prolonged lamivudine therapy 显示文摘 | Gwak GY Huh W Lee DH | 2007 | Transplant Proc2007，39，10： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员